Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Contineum TherapeuticsCTNM -1.37%17 1-Year ROIIC % is -223.57 as of Jun. 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 1,336 Biotechnology companies, Contineum Therapeutics ranks worse than 78.44% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Contineum Therapeutics's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was -223.57%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Contineum Therapeutics's 1-Year ROIIC % or its related term are showing as below:
CTNM's 1-Year ROIIC % is ranked worse than 78.44% of 1336
companies
in the Biotechnology industry
Industry Median: -8.825
vs CTNM: -223.57
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Contineum Therapeutics 1-Year ROIIC % Related Terms
Contineum Therapeutics 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Contineum Therapeutics's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTNM vs FDMT, PRME, ARVN: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Contineum Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Contineum Therapeutics 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Contineum Therapeutics's 1-Year ROIIC % falls into.
Contineum Therapeutics's 1-Year ROIIC % for the quarter that ended in Jun. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -66.379 (Jun. 2026) - -66.033 (Jun. 2025) )
/
( 12.593 (Jun. 2026) - 9.285 (Jun. 2025) )
=
-0.346
/
3.308
=
-10.46%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Contineum Therapeutics (CTNM) has a 1-Year ROIIC % of -223.57 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Contineum Therapeutics and its competitors. According to the industry distribution chart, Contineum Therapeutics ranks #1048 out of 1336 companies in the Biotechnology industry, placing it in the top 78.4%.
Is Contineum Therapeutics' 1-Year ROIIC % too high?
Contineum Therapeutics' current 1-Year ROIIC % is -223.57. Based on the distribution chart, Contineum Therapeutics ranks #1048 out of 1336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' 1-Year ROIIC % compare to FDMT and PRME?
According to the Biotechnology industry distribution chart, Contineum Therapeutics ranks #1048 out of 1336 companies for 1-Year ROIIC %. This places Contineum Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Contineum Therapeutics and its competitors. Contineum Therapeutics's current 1-Year ROIIC % is -223.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current 1-Year ROIIC % of -223.57. The current 1-Year ROIIC % is -223.57. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current 1-Year ROIIC % is -223.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score
Get the complete analysis for CTNM
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTNM has been successfully added to your 
